Translational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)
临床前和已确诊狼疮分子分析转化中心 (COMPEL)
基本信息
- 批准号:9766075
- 负责人:
- 金额:$ 134万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-22 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:Abnormal CellAddressAllelesAntibodiesAntibody ResponseAntigen-Antibody ComplexAntigen-Presenting CellsAntigensAttentionAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune ProcessAutoimmunityB-LymphocytesBacteriaBasic ScienceBenignBioinformaticsBiological SciencesBloodCD4 Positive T LymphocytesCaringCellular biologyClinicalClinical ManagementClonal ExpansionClone CellsCloningCollaborationsComplexComputational ScienceCulture-independent methodsDNADatabasesDeoxyribonucleasesDevelopmentDiseaseEnvironmental Risk FactorExanthemaFamily StudyFlareGenesGeneticGenetic VariationGnotobioticGoalsHeart DiseasesHospitalsHumanImmuneImmune responseImmune systemImmunoglobulin AImmunoglobulin GIndividualInflammatoryInjuryIntestinesInvestigationKidneyLaboratoriesLupusMediatingMedicalMedicineModelingMolecularMolecular ProfilingMucosal ImmunityMusMusculoskeletalNatureNeonatal lupus erythematosusNew YorkPathogenesisPathogenicityPathologicPathologyPatientsPenetrancePersonsPhenotypePredispositionPreventionReceptors, Antigen, B-CellRegistriesReportingResearchResearch PersonnelResearch Project GrantsResourcesRestRibosomal RNARiskRoleSamplingScienceScientistSeveritiesSpecificitySumSurveysSusceptibility GeneSystemic Lupus ErythematosusT-LymphocyteTechnologyTestingTherapeuticTimeTissuesTreatment EfficacyUniversitiesWidespread DiseaseWomanWorkarthropathiesbacterial communitybasebiobankcohortcommensal microbescross reactivityds-DNAethnic diversitygenome wide association studyin vivoinsightmedical schoolsmicrobialmicrobiomeoffspringpathobiontperipheral bloodpre-clinicalprogramsracial and ethnicracial diversityresponsestatisticstranslational study
项目摘要
NYU School of Medicine and collaborating clinical and basic investigators in Medicine and Pathology propose
to establish the Translational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)
comprising 3 Projects, 2 Research Cores, and an Administrative Core. The overarching goal is to elucidate the
mechanisms by which Systemic Lupus Erythematosus (SLE), a prototypic yet clinically and immuno-
molecularly heterogeneous autoimmune disease, is initiated and perpetuated. COMPEL leverages a) a unique
cohort of asymptomatic women presenting with breakdown in B cell tolerance identified because of neonatal
lupus (NL) in an offspring (Research Registry for Neonatal Lupus, RRNL) and b) a robustly phenotyped cohort
of established SLE patients spanning diverse racial backgrounds and with a high penetrance of serious illness
(NYU Cohort). Project 1 profiles anti-Ro preclinical and clinical autoimmunity to identify blueprints of an
immune system that remains preclinical, and in individuals who have progressed to overt disease. The
approach rests on identifying associations between host genetics, the microbiome, and the phenotype of CD4+
T cells, which constitute an immune triumvirate of T cells, antigen-presenting cells with an MHC II-defined
specificity towards particular microbial taxa, and B cells. Project 2 explores microbiome pathobionts and SLE
pathogenesis to understand how specific candidate pathobiont bacterial isolates contribute to overt SLE
disease and flares, and to peripheral blood expansion of disease-associated B cell clones. Human intestinal
IgA responses can be both specific for in vivo eliciting bacteria, and often cross-reactive with self-antigens. Yet,
the gut-associated B cell response has not been investigated in SLE as a driver of autoimmune disease.
Project 3 focuses on DNASE1L3, a unique secreted DNase that is essential for protection against SLE. We
have shown that DNASE1L3 digests DNA in circulating microparticles and antibody (Ab) reactivity to
microparticle antigens is frequently detected in SLE. The project will explore Ab responses to DNASE1L3-
sensitive microparticle antigens in preclinical and established SLE patients; molecularly characterize these
antigens and test DNASE1L3 as a therapeutic. The Research Technology Core brings advanced technology
for NGS applications of large scale autoAb gene repertoire analyses from human B cell samples and will sort
intestinal IgA-coated bacteria profiled by 16S rRNA microbiome surveys. The Clinical Core comprises the
database (REDCap) and biobank (Freezerworks) of 3 cohorts (RRNL, NYU Lupus Cohort, healthy controls) to
facilitate translational studies. The Administrative Core supports organizational, financial and reporting
activities. The analytic team brings expertise in biostatics, genetic statistics, bioinformatics and computational
science. External advisors covering translational SLE, the microbiome, T cell biology and mucosal immunity,
and 2 lay persons with ties to NL, will provide overall review and with COMPEL select Pilot/Feasibility Projects
to leverage program resources and expand thematic objectives.
纽约大学医学院和合作的临床和基础医学和病理学研究人员提出
在临床前和已确诊的狼疮中建立分子图谱翻译中心(COMPELL)
包括3个项目、2个研究核心和1个行政核心。首要目标是阐明
系统性红斑狼疮(SLE)是一种典型的临床和免疫学疾病。
分子异质性的自身免疫性疾病是始发并持续存在的。强制利用a)独特的
因新生儿而出现B细胞耐受性崩溃的无症状妇女队列
后代中的狼疮(NL)(新生儿狼疮研究登记,RRNL)和b)一个强健的表型队列
已确诊的SLE患者跨越不同种族背景和严重疾病的高外显率
(纽约大学队列)。项目1介绍抗Ro临床前和临床自身免疫以确定一个蓝图
仍处于临床前状态的免疫系统,以及已进展为显性疾病的个体。这个
方法依赖于确定宿主遗传学、微生物组和CD4+表型之间的关联
T细胞,它构成了T细胞的免疫三重奏,抗原提呈细胞具有MHC II定义
对特定微生物类群和B细胞的特异性。项目2探索微生物组致病细菌和系统性红斑狼疮
发病机制以了解特定的候选致病细菌分离株如何对显性SLE起作用
疾病和耀斑,以及与疾病相关的B细胞克隆的外周血液扩张。人体肠道
免疫球蛋白反应既可以是体内激发细菌的特异性反应,也可以与自身抗原交叉反应。然而,
在系统性红斑狼疮中,肠道相关的B细胞反应尚未被作为自身免疫性疾病的驱动因素进行研究。
项目3的重点是DNASE1L3,这是一种独特的分泌DNA酶,对预防SLE至关重要。我们
已表明DNASE1L3消化循环微粒中的DNA和抗体(Ab)对
在系统性红斑狼疮中经常检测到微粒抗原。该项目将探索对DNASE1L3的抗体反应-
临床前和已确诊的SLE患者中的敏感微粒抗原;分子特征
并检测DNASE1L3作为一种治疗方法。研究技术核心带来先进技术
对于NGS应用大规模的人类B细胞样本中的自体抗体基因库分析,并将进行排序
16S rRNA微生物组分析肠道IgA包被细菌。临床核心包括
3个队列(RRNL、纽约大学狼疮队列、健康对照)的数据库(RedCap)和生物库(Freezerworks)
促进翻译研究。行政核心支持组织、财务和报告
活动。分析小组带来了生物静力学、遗传统计学、生物信息学和计算方面的专业知识
科学。翻译类系统性红斑狼疮、微生物组、T细胞生物学和粘膜免疫的外部顾问,
和2名与NL有联系的非专业人员,将提供全面审查,并强制选择试点/可行性项目
利用计划资源,扩大主题目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jill P Buyon其他文献
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade
母体抗 SSA/Ro 自身抗体经滋养层转运至有快速进展性心脏损伤胎儿中的证据:对新生儿 Fc 受体阻断的意义
- DOI:
10.1016/s2665-9913(24)00331-x - 发表时间:
2025-01-01 - 期刊:
- 影响因子:16.400
- 作者:
Jill P Buyon;Philip M Carlucci;Bettina F Cuneo;Mala Masson;Peter Izmirly;Nalani Sachan;Justin S Brandt;Shilpi Mehta-Lee;Marc Halushka;Kristen Thomas;Melanie Fox;Colin KL Phoon;Achiau Ludomirsky;Ranjini Srinivasan;Garrett Lam;Benjamin J Wainwright;Nicola Fraser;Robert Clancy - 通讯作者:
Robert Clancy
Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside
新生儿红斑狼疮的心脏表现:管理指南,整合实验台和病床旁的线索
- DOI:
10.1038/ncprheum1018 - 发表时间:
2009-03-01 - 期刊:
- 影响因子:32.700
- 作者:
Jill P Buyon;Robert M Clancy;Deborah M Friedman - 通讯作者:
Deborah M Friedman
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
索马鲁肽治疗 2 型糖尿病患者的心脏病研究
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Devyn Zaminski;Amit Saxena;P. Izmirly;Jill P Buyon;H. M. Belmont - 通讯作者:
H. M. Belmont
Jill P Buyon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jill P Buyon', 18)}}的其他基金
Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
停止使用羟氯喹治疗老年狼疮病 (SHIELD)
- 批准号:
10594743 - 财政年份:2023
- 资助金额:
$ 134万 - 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
- 批准号:
10668437 - 财政年份:2022
- 资助金额:
$ 134万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain Supplement
狼疮组学皮肤肾脏调查小组 (LOCKIT) - 疼痛补充剂
- 批准号:
10861419 - 财政年份:2022
- 资助金额:
$ 134万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
- 批准号:
10452169 - 财政年份:2022
- 资助金额:
$ 134万 - 项目类别:
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)
狼疮组学皮肤肾研究小组 (LOCKIT)
- 批准号:
10596281 - 财政年份:2022
- 资助金额:
$ 134万 - 项目类别:
HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
健康:利用流行病学促进狼疮治疗和健康
- 批准号:
10552857 - 财政年份:2022
- 资助金额:
$ 134万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10250529 - 财政年份:2020
- 资助金额:
$ 134万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10440476 - 财政年份:2020
- 资助金额:
$ 134万 - 项目类别:
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
监测和治疗以预防胎儿房室传导阻滞可能很快发生(STOP BLOQ)
- 批准号:
10644022 - 财政年份:2020
- 资助金额:
$ 134万 - 项目类别:
Mechanisms of DNA-Specific Autoimmunity in Systemic Lupus Erythematosus
系统性红斑狼疮 DNA 特异性自身免疫机制
- 批准号:
10374852 - 财政年份:2018
- 资助金额:
$ 134万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 134万 - 项目类别:
Research Grant